Sanofi, Regeneron to make Praluent more accessible and affordable for patients with greatest health risk and unmet need

To help ensure more affordable and timely access to patients most in need, Sanofi and Regeneron Pharmaceuticals, will offer US payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent (alirocumab) injection in alignment with a new value assessment for high-risk patients from the US Institute for Clinical and Economic Review (ICER).  The companies will take a precision medicine approach, to address the burden of cardiovascular disease, focusing efforts on high-risk patients most vulnerable for future cardiovascular (CV) events, such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite maximally-tolerated statin therapy.